Lancet Gastroenterology & Hepatology

Article	Citations
GORD: pain, PPIs, and preciseness	1641
Viral hepatitis: time for action	579
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30	535
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy	476
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply	462
Lucky: Learning to Live Again	438
Research in Brief	354
Immune checkpoint inhibitors in colorectal cancer: dream and reality	353
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11	323
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design	287
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma	269
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension	261
Treatment withdrawal in Crohn's disease: slowly becoming clearer	247
Trends in alcohol-specific deaths in the UK and industry responses	228
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship	227
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium	225
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled	224
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study	220
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives	213
EASL Congress 2024	205
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial	203
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement	191
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study	188
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial	185
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial	178

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t	173
ACG 2024	172
Global multi-stakeholder endorsement of the MAFLD definition	172
Long-term VEDOKIDS results: implications for practice and research	166
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?	162
Availability of point-of-care HBV tests in resource-limited settings	144
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply	142
Management of portal vein thrombosis in cirrhosis	141
Sex and gender in inflammatory bowel disease outcomes and research	140
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study	138
Idiopathic gastroparesis consensus misses the patient's voice	135
Research in Brief	134
Has the time come for a systematic top-down approach in Crohn's disease?	131
Uptick of food allergies in recent years—real or epiphenomenon?	131
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply	128
Resmetirom for NASH: balancing promise and prudence	125
Addressing the rise of early-onset colorectal cancer	119
Local and systemic therapy in liver cancer: the quest for synergy	117
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere	115
The potential of ctDNA in locoregional therapies for colorectal cancer	114
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)	112
All roads lead to the gut–brain microbiome network	107
Water and sanitation for all	107
Bringing organ preservation closer for selected patients with rectal cancer	107
Rare cause of dysphagia in a young woman	106
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47	103
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis	102
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial	102
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study	102
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada	101
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study	101
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised p	100
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review	98
Hypovolaemic phlebotomy for hepatic resection	94
Unifying the approach to tackling inequalities in liver health: learning from working with underserved populations	93
Lifting the minority tax in gastroenterology and hepatology	92
The Year My Life Went Down the Toilet	90
Management of malignant bowel obstruction – Authors' reply	89
A women-focused matrix mentorship programme in gastroenterology	89
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B	87
Urgent action needed to achieve viral hepatitis elimination	87
The growth of faecal microbiota transplantation in the UK: time for a registry?	86
Research in Brief	85
Dangerous Medicine	84
Managing inflammatory bowel disease: what to do when the best is unaffordable?	83
Practicalities accessing precision medicine in biliary tract cancer	81
Research in Brief	79
Another arrow in the NASH quiver?	78
Robotic versus laparoscopic surgery for middle and low rectal cancer	77
18th Congress of the European Crohn's and Colitis Organisation	75

An unusual complication after a variceal glue injection	74
Britta Siegmund: answering the big questions in IBD	73
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions	73
CEND-1: a game changer for pancreatic cancer chemotherapy?	73
Closing the gender gap: building a successful career and leadership in research as a female gastroenterologist	72
Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities	71
Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED	70
Shitbag: the story of a diagnosis	70
Redefining palliation in malignant gastric outlet obstruction	69
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment de	67
Effects of lyophilised faecal filtrate compared with lyophilised donor stool on Clostridioides difficile recurrence: a multicentre, randomised, double-blinded, non-inferiority trial	67
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial	66
Long-term safety of faecal microbiota transplantation for gastrointestinal diseases in China	66
Scientific and medical evidence informing expansion of hepatitis B treatment guidelines	66
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial	65
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial	63
Machine learning-based automated sponge cytology for screening of oesophageal squamous cell carcinoma and adenocarcinoma of the oesophagogastric junction: a nationwide, multicohort, prospective study	61
Immune-checkpoint blockade in surgical management of gastric or gastro-oesophageal junction adenocarcinoma	60
Primary biliary cholangitis and the narrowing gap towards optimal disease control	60
Research in brief	59
Bowel cancer prevention: are we missing an opportunity?	58
Management of portal vein thrombosis in cirrhosis – Authors' reply	58
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis	57
Primary intestinal lymphangiectasia	57
Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines	56
Alcohol and health: time for Europe to sober up	56
Correction to Lancet Gastroenterol Hepatol 2023; 8: 908–18	56
Lessons learned from the BOSS trial	56
Correction to Lancet Gastroenterol Hepatol 2021; 6: 781	56
Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations	55
Combining systemic and local therapies for hepatocellular carcinoma	55
Induction of microRNA-124 as a novel therapeutic concept in ulcerative colitis	54
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny	54
COP27 Climate Change Conference: urgent action needed for Africa and the world	54
The problem of antimicrobial resistance in chronic liver disease	53
The world is failing on hunger	53
Compensation advised for UK victims of contaminated blood scandal	53
Hypovolaemic phlebotomy in patients undergoing hepatic resection at higher risk of blood loss (PRICE-2): a randomised controlled trial	52
The top 10 research priorities for inflammatory bowel disease in children and young adults: results of a James Lind Alliance Priority Setting Partnership	52
Research in Brief	52
Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study	51
Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review	51
Increasing burden of colorectal cancer in China	50
Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework	50
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease	50
The intestinal barrier: a pivotal role in health, inflammation, and cancer	49
Watch and wait for rectal cancer: towards data-informed surveillance	48
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study	48
Does filgotinib work for Crohn's disease?	48
PANTS extension study: how best to use anti-TNF drugs in Crohn's disease	48
Diet or optimised medical therapy for people with irritable bowel syndrome	48
HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus	47
Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics	47
Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials	47
Correction to Lancet Gastroenterol Hepatol 2025; 10: 715–25	46
Early-onset colorectal cancer: Hollyoaks tackles taboos and raises awareness	46
DEI in gastroenterology and hepatology	45
The role of [18F]FDG and [18F]FCH PET-CT in hepatocellular carcinoma with cirrhosis	45
Research in Brief	45
World Hepatitis Day 2025: elimination at a critical juncture	45
Lessons and open questions in borderline resectable pancreatic cancer	44
The British Association for the Study of the Liver commitment to equality, diversity, and inclusivity	44
Pre-emptive TIPS for gastric variceal bleeding in patients with cirrhosis (GAVAPROSEC): an open-label randomised clinical trial	43
The costs of inadequate toilet coverage in the Philippines	43
Peroral endoscopic myotomy versus pneumatic dilation for achalasia	43
The liver–brain axis in metabolic dysfunction-associated steatotic liver disease	43
Standardising early liver transplantation for severe alcohol-related hepatitis	43
Gastroenterology training in Africa: an assessment of curriculum and perception	43
Faecal microbiota transplantation for first and second episodes of Clostridioides difficile infection	43
Spleen stiffness in portal hypertension algorithms: the next advance	42
Elimination of hepatitis B requires recognition of catastrophic costs for patients and their families	42
Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD	42
Combination locoregional and systemic therapies in hepatocellular carcinoma	41
Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial	41
Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	41
Oncological safety of laparoscopic surgery for low rectal cancer	40
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised contro	40
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial	40
Time for a treat all approach for hepatitis B	39
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial	39

Infliximab rescue therapy in acute severe ulcerative colitis: more does not equal better	37
Accelerating point-of-care HCV viral load testing	36
The International Liver Congress 2022	36
Research in Brief	36
Endoscopic interventions for stricturing Crohn's disease	36
A coordinated multipronged attack: integrated care is the future for gastroenterology	36
Is the attenuated humoral response to COVID-19 vaccination in anti-TNF users relevant?	36
Inequities in alcohol-related harm in the Philippines	35
More is not always better for novel hepatitis B therapies	35
Research in Brief	35
Inclusion of patients with isolated ulcerative proctitis in clinical trials	34
Launch of the International Living Donor Liver Transplantation Outcomes Registry	34
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions	33
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis	33
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study	33
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from	32
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study	31
MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomise	31
An open letter to Gavi: hepatitis B birth dose vaccine can't wait	31
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy	30
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study	30
No accident: the UK infected blood scandal	29
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy	29
The Liver Meeting 2023	29
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial	29
Haematopoietic stem-cell transplantation in Crohn's disease	28
Hypovolaemic phlebotomy to reduce the need for perioperative transfusion: a price worth paying?	28
Robotic pancreatoduodenectomy: preparing for the future	28
Tackling obesity: drugs are only part of the solution	28
Chronic Boom	28
Local ablation in pancreatic cancer: some answers and more questions	28
Top ten research priorities for alcohol use disorder and alcohol-related liver disease: results of a multistakeholder research priority setting partnership	27
The urgent need to end hepatitis B stigma and discrimination	27
Implementing metabolic dysfunction-associated steatotic liver disease guidelines in patients with type 2 diabetes	27
Retina and liver fibrosis screening for patients with type 2 diabetes	27
17th Congress of ECCO	26
Refining the faecal incontinence core outcome set – Authors' reply	26
Oral faecal microbiota transplantation in ulcerative colitis	25
Vedolizumab in paediatric IBD: a huge step forward but not there yet	25
Comparison of trends in early-onset colorectal cancer in North America and Europe	25
Challenging stigma around alcohol misuse	25
Terlipressin for hepatorenal syndrome: opportunities and challenges	25
Lessons from a trial of colesevelam for bile acid diarrhoea	24
Research in Brief	24
Peroral endoscopic myotomy versus pneumatic dilation in treatment-naive patients with achalasia – Authors' reply	24
Séverine Vermeire: advancing patient-centred research in IBD	24
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated rand	23
A new chapter in the campaign to eliminate viral hepatitis?	23
Ranking treatments in the network meta-analysis should consider the certainty of evidence – Authors' reply	23
Cultural competence in the delivery of nutrition and symptom care in irritable bowel syndrome	22
A call for advocacy and patient voice to eliminate hepatitis B virus infection	22
Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial	21
Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial	21
Global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis: the International Club of Ascites GLOBAL AKI prospective, multicentre, cohort study	21
A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia	21
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial	20
Metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after extensive versus partial colectomy in the Netherlands: a retrospective cohort study	20
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial	20
Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial	20
Psychological therapies in inflammatory bowel disease	20
Diet or optimised medical therapy for people with irritable bowel syndrome	20
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based th	20
An important step towards the long-term treatment of eosinophilic oesophagitis	19
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis	19
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary?	19
Non-coeliac gluten sensitivity: from Salerno to Rome	19
Research in Brief	19
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? – Author's reply	19
Research in Brief	18
Expression of concern—Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre random	18
Africa CDC's viral hepatitis prevention and control programme: a continental initiative to support elimination programmes	18
Financing viral hepatitis: catalysing action for impact	18
Septic arthritis: a presentation of Crohn's disease	18
Liver disease admissions in the UK are increasing, urgently needing local and national solutions	18
Are all post-ESWL pancreatitis events clinically significant?	17
Variceal embolisation plus TIPS for variceal bleeding	17
Intraoperative fluorescence angiography with indocyanine green to prevent anastomotic leak in rectal cancer surgery (IntAct): an unblinded randomised controlled trial	17
Single CT colonography versus three rounds of faecal immunochemical test for population-based screening of colorectal cancer (SAVE): a randomised controlled trial	17
Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel	16
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials	16
NAFLD prevalence and severity in overweight and obese populations	16
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial	16
Antibiotic treatment versus appendicectomy for acute appendicitis in adults: an individual patient data meta-analysis	16
Research in Brief	15
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trial – Authors' reply	15
Weighing the benefits of screening for early-onset colorectal cancer	15
Treatment of hepatocellular carcinoma in sub-Saharan Africa: challenges and solutions	15
Pathogens don't respect politicians: US federal disruption poses a new threat to global public health	14
Targeting type 2 immune responses to treat eosinophilic gastritis	14
Uncouplers of mitochondrial oxidation in non-alcoholic fatty liver disease	14
A path to global cirrhosis health equity	14
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease	13
ACG 2021	13
The promise of automated liver disease risk stratification in primary care	13
Retina and liver fibrosis screening for patients with type 2 diabetes – Authors' reply	13